AI Science Tracker

Machine-learning models identify cerebrospinal-fluid protein signatures for multiple-sclerosis activity and disability progression

Linköping University; University of Skövde; Karolinska Institutet and Karolinska University Hospital; collaborating Swedish institutions · 30 Oct 2023 · medicine

Discovery

Machine-learning models identify cerebrospinal-fluid protein signatures for multiple-sclerosis activity and disability progression

Using Olink proteomics of 1,463 proteins in CSF and plasma from two prospective Swedish cohorts, the study trained prediction models for multiple-sclerosis diagnosis, 2-year disease activity and long-term disability worsening. Lower CSF neurofilament light (NfL) predicted absence of disease activity at two years (replication AUC 0.77). A stepwise model using 11 CSF proteins (CXCL13, LTA, FCN2, ICAM3, LY9, SLAMF7, TYMP, CHI3L1, FYB1, TNFRSF1B and NfL) predicted normalized age-related MS severity; subgroup classification AUCs in the replication cohort ranged from 0.88 to 0.90.

Technology: Stepwise logistic regression for diagnosis and disease activity; stepwise linear regression for long-term disability severity

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Using Olink proteomics of 1,463 proteins in CSF and plasma from two prospective Swedish cohorts, the study trained prediction models for multiple-sclerosis diagnosis, 2-year disease activity and long-term disability worsening.
  • Still unknown: The study included 143 people with early-stage MS and 43 healthy controls across discovery and replication cohorts; the replication MS cohort had 51 participants. The 2-year disease-activity comparison in replication was especially small (45 with activity versus 5 without). The 11-protein severity model predicted observational disability scores rather than treatment benefit. The plasma severity model had only 12 eligible replication samples and performed less convincingly. These are cohort-level results, not a clinically validated diagnostic assay or independent replication by another research group.
  • AI role: The study used statistical differential-expression testing to select disease-associated candidate proteins, then fitted logistic-regression models to predict MS diagnosis and 2-year disease activity and a linear-regression model to predict long-term normalized age-related MS severity. Stepwise feature selection produced the protein combinations; the frozen models were evaluated in a separate prospective cohort.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10616092/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 112 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.